The negative results of Fshr mRNA expression in the endothelial cells of LNCaP xenograft murine vessels, supported by the negative expression of FSHR in HUVECs (Rivero-Muller et al. 2007), indicate that FSHR expression in the prostate cancer vasculature (Radu et al. 2010), as a potential therapeutic target, requires further confirmation. This evidence concerns the gene FSHR and prostate carcinoma.